PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28274247-0	2017	Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.	Gossypol	0-8	MDM2 proto-oncogene	Homo sapiens	51-55	
28274247-4	2017	Because MDM2 is an RNA-binding protein and its targets include VEGF mRNA, we investigated whether gossypol has an inhibitory effect on MDM2-VEGF.	Gossypol	98-106	MDM2 proto-oncogene	Homo sapiens	135-144	
28274247-5	2017	METHODS: UV cross-linking and RNA binding assay, isothermal titration calorimetry assay, and ubiquitination assay were performed to determine mechanisms by which gossypol functions as a dual inhibitor of MDM2 and VEGF.	Gossypol	162-170	MDM2 proto-oncogene	Homo sapiens	204-208	
28274247-6	2017	The effect of gossypol on MDM2 and VEGF expression, cancer cell apoptosis, tumor growth and VEGF-mediated angiogenesis were studied in vitro and in vivo in different human breast cancer models with a different p53 status.	Gossypol	14-22	MDM2 proto-oncogene	Homo sapiens	26-30	
28274247-7	2017	RESULTS: We observed that gossypol inhibited expression of both MDM2 and VEGF in human breast cancer cells with either wild-type or mutant p53.	Gossypol	26-34	MDM2 proto-oncogene	Homo sapiens	64-68	
28274247-8	2017	A nechanistic study further demonstrated that, through disrupting the interaction between MDM2 protein and VEGF mRNA, gossypol induced MDM2 self-ubiquitination and decreased VEGF translation simultaneously, which resulted in both apoptosis and anti-angiogenesis effects.	Gossypol	118-126	MDM2 proto-oncogene	Homo sapiens	90-94	
28274247-11	2017	CONCLUSION: Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.	Gossypol	12-20	MDM2 proto-oncogene	Homo sapiens	63-67